SCYX SCYNEXIS INC

SCYNEXIS Announces Submission of New Drug Application to the U.S. Food and Drug Administration for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infection

SCYNEXIS Announces Submission of New Drug Application to the U.S. Food and Drug Administration for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infection
EN
14/10/2020

Underlying

SCYXSCYNEXIS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCYNEXIS INC

 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Announces Multiple Presentations Highlighting Data from its S...

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12) Oral presentation will feature data demonstrating SCY-247 in vitro activity against C. auris strains, including isolates with mutations commonly associated with echinocandin-resistanceAdditional poster presentations highlight SCY-247’s broad spectrum of antifungal activity, against Candida species, including multidrug- and pandrug-resistant C. auris and Aspergillus speciesCompany anticipates reporting Phase 1 Single Ascending D...

September 4, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conf...

SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025 JERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Scynexis senior leadership team will participate in the H.C. Wainwright 27th Annual Global Conference. Date: Wednesday September 10, 2025Format: In-person presentation and 1x1 meetingsTime: 10:30 a.m.-11:00 a.m. ETLocation: New York, NY If you are intere...

August 25, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Co...

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary of the new patient dosing; as previously disclosed GSK disputes these milestone payments.  SCYNEXIS vigorously disagrees with GSK’s position and is working towards resolving this disagreement; SCYNEXIS is actively working with GSK to transfer the BREXAFEMME New Drug Application (NDA) to G...

August 13, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously disclosed GSK disputes these milestone payments, and SCYNEXIS vigorously disagrees with their position JERSEY CITY, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant i...

May 28, 2025 1 EN
 PRESS RELEASE
Free
SCYX SCYNEXIS INC

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Cor...

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update Ibrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemme.Hansoh recently received Chinese (NMPA) approval for ibrexafungerp in the treatment of acute VVC. SCYNEXIS will receive a milestone payment from Hansoh upon commercialization as well as royalties of approximately 10% on China sales.Presented positive preclinical data for its second-generation fungerp candidate...

May 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch